Evidence map›Paper›PMID 28678607›Full record

ArticleHuman vaccines & immunotherapeutics2017

HIV Env conserved element DNA vaccine alters immunodominance in macaques.

Xintao Hu, Antonio Valentin, Margherita Rosati, Siriphan Manocheewa, Candido Alicea, Bhabadeb Chowdhury, Jenifer Bear, Kate E Broderick, Niranjan Y Sardesai, Sylvie Le Gall and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Impact of TJournal of virology · 2020
    Article
  7. Review
  8. Acute-Phase CD4Journal of virology · 2018
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Xintao Hua Human Retrovirus Pathogenesis Section, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Antonio Valentinb Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Margherita Rosatib Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Siriphan Manocheewac Departments of Microbiology , University of Washington , Seattle , WA , USA.
Candido Aliceaa Human Retrovirus Pathogenesis Section, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Bhabadeb Chowdhuryb Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Jenifer Beara Human Retrovirus Pathogenesis Section, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Kate E Broderickd Inovio Pharmaceuticals, Inc. , Plymouth Meeting , PA , USA.
Niranjan Y Sardesaid Inovio Pharmaceuticals, Inc. , Plymouth Meeting , PA , USA.ORCID 0000-0001-6920-1167
Sylvie Le Galle Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School , Cambridge , MA , USA.
James I Mullinsc Departments of Microbiology , University of Washington , Seattle , WA , USA.
George N Pavlakisb Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Barbara K Felbera Human Retrovirus Pathogenesis Section, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
Frederick National Laboratory for Cancer Research · USInovio Pharmaceuticals (United States) · USUniversity of Washington · USHarvard University · US

Funding

Prevention of AIDSZIABC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$30.0M
Immunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI COREY, LAWRENCE · 2003 to 2014
$20.5M
NIAID NIH HHS P01 AI057005
6 · The paper itself

Abstract

Sequence diversity and immunodominance are major obstacles in the design of an effective vaccine against HIV. HIV Env is a highly-glycosylated protein composed of 'conserved' and 'variable' regions. The latter contains immunodominant epitopes that are frequently targeted by the immune system resulting in the generation of immune escape variants. This work describes 12 regions in HIV Env that are highly conserved throughout the known HIV M Group sequences (Env CE), and are poorly immunogenic in macaques vaccinated with full-length Env expressing DNA vaccines. Two versions of plasmids encoding the 12 Env CE were generated, differing by 0-5 AA per CE to maximize the inclusion of commonly detected variants. In contrast to the full-length env DNA vaccine, vaccination of macaques with a combination of these 2 Env CE DNA induced robust, durable cellular immune responses with a significant fraction of CD8

Indexed as

Conserved SequenceAIDS VaccinesAnimalsCD8-Positive T-LymphocytesCytotoxicity, Immunologicenv Gene Products, Human Immunodeficiency VirusHIV-1HumansMacaca mulattaVaccines, DNAAIDS Vaccinesenv Gene Products, Human Immunodeficiency VirusVaccines, DNAconserved epitopescytotoxic T cellsDNA vaccineEnvHIVimmunizationprime-boostrhesus macaquesubdominant epitopesvariable epitopes

Identifiers

PMID28678607
PMCPMC5718827
OpenAlexW2727282733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.